The influence of certain plant substances and their chemopreventive activity in ovarian cancer.

A steadily growing number of studies have confirmed the beneficial effects of plant-derived substances (preparations) on the effectiveness of pharmacotherapy for ovarian cancer. A prior or parallel application of plant-derived substances and chemotherapy could be the way to strengthen the classic pharmacological treatment. Our paper presents several plant-derived substances with proven antiproliferative activities, in which phenolic and flavonoid bioactive compounds dominate, with particular emphasis on ovarian cancer cells. We are of the opinion that our paper will contribute to better understanding of the molecular basis for the positive interaction effect of concomitant application of the abovementioned plant substances with certain cytostatics. Also, this work may increase the number of preclinical in vivo experiments using these and other phenolic, flavonoid-rich plant substances to better understand their efficacy and safety and, in the future, to initiate clinical trials in this field.

[1]  Khairol Amali Bin Ahmad,et al.  The Chinese herbs Scutellaria baicalensis and Fritillaria cirrhosa target NFκB to inhibit proliferation of ovarian and endometrial cancer cells , 2015, Molecular carcinogenesis.

[2]  Y. Hao,et al.  Sensitisation of ovarian cancer cells to cisplatin by flavonoids from Scutellaria barbata , 2014, Natural product research.

[3]  K. Sim,et al.  Cytotoxic effect of Alpinia scabra (Blume) Náves extracts on human breast and ovarian cancer cells , 2013, BMC Complementary and Alternative Medicine.

[4]  I. Bairati,et al.  A two-stage, single-arm, phase II study of EGCG-enriched green tea drink as a maintenance therapy in women with advanced stage ovarian cancer. , 2013, Gynecologic oncology.

[5]  J. A. Nogueira-Machado,et al.  The anti-oxidant properties of isothiocyanates: a review. , 2013, Recent patents on endocrine, metabolic & immune drug discovery.

[6]  P. Surowiak,et al.  Quercetin inhibits proliferation and increases sensitivity of ovarian cancer cells to cisplatin and paclitaxel. , 2013, Ginekologia polska.

[7]  A. Huntley,et al.  Green tea and green tea catechin extracts: an overview of the clinical evidence. , 2012, Maturitas.

[8]  T. Starlin,et al.  Leaf extract of Alpinia purpurata (Vieill.) K. Schum screened for its phytochemical constituents and antibacterial and anticancer activities. , 2012, Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine.

[9]  P. Beale,et al.  Studies on combination of platinum drugs cisplatin and oxaliplatin with phytochemicals anethole and curcumin in ovarian tumour models. , 2012, Anticancer research.

[10]  S. Theocharis,et al.  Cranberry as promising natural source of potential anticancer agents: current evidence and future perspectives. , 2012, Anti-cancer agents in medicinal chemistry.

[11]  P. Beale,et al.  Synergism from combinations of cisplatin and oxaliplatin with quercetin and thymoquinone in human ovarian tumour models. , 2011, Anticancer research.

[12]  Xuewu Zhang,et al.  In vitro antitumor activity of broccolini seeds extracts. , 2011, Scanning.

[13]  Ghazaleh Ghavami,et al.  Cheminformatics-based selection and synergism of herbal extracts with anticancer agents on drug resistance tumor cells - ACHN and A2780/CP cell lines , 2011, Comput. Biol. Medicine.

[14]  Fei Guan,et al.  Cancer prevention by tea: Evidence from laboratory studies. , 2011, Pharmacological research.

[15]  K. M. Schaich,et al.  Phytochemicals of Cranberries and Cranberry Products: Characterization, Potential Health Effects, and Processing Stability , 2009, Critical reviews in food science and nutrition.

[16]  R. Nussbaum,et al.  Cranberry proanthocyanidins are cytotoxic to human cancer cells and sensitize platinum‐resistant ovarian cancer cells to paraplatin , 2009, Phytotherapy Research.

[17]  M. Li‐Weber.  New therapeutic aspects of flavones: the anticancer properties of Scutellaria and its main active constituents Wogonin, Baicalein and Baicalin. , 2009, Cancer treatment reviews.

[18]  Jianpin Liu,et al.  Green tea (Camellia sinensis) and cancer prevention: a systematic review of randomized trials and epidemiological studies , 2008, Chinese medicine.

[19]  Min-Sung Kim,et al.  Antiproliferative effect of Scutellaria barbata D. Don. on cultured human uterine leiomyoma cells by down‐regulation of the expression of Bcl‐2 protein , 2008, Phytotherapy research : PTR.

[20]  M. S. Pérez-Gutiérrez,et al.  Effect of Plantago major on cell proliferation in vitro. , 2006, Journal of ethnopharmacology.

[21]  D. M. Morré,et al.  Medicinal benefits of green tea: Part I. Review of noncancer health benefits. , 2005, Journal of alternative and complementary medicine.

[22]  Young-Choon Lee,et al.  Regulation of IGF-I production and proliferation of human leiomyomal smooth muscle cells by Scutellaria barbata D. Don in vitro: isolation of flavonoids of apigenin and luteolin as acting compounds. , 2005, Toxicology and applied pharmacology.

[23]  Andy H. Lee,et al.  Green tea consumption enhances survival of epithelial ovarian cancer , 2004, International journal of cancer.

[24]  Young-Chae Chang,et al.  Inhibitory effects of Scutellaria barbata D. Don on human uterine leiomyomal smooth muscle cell proliferation through cell cycle analysis. , 2004, International immunopharmacology.

[25]  Young-Choon Lee,et al.  Differential Inhibition of Scutellaria barbata D. Don (Lamiaceae) on HCG‐Promoted Proliferation of Cultured Uterine Leiomyomal and Myometrial Smooth Muscle Cells , 2004, Immunopharmacology and immunotoxicology.

[26]  K. Smith-McCune,et al.  Aqueous extract of herba Scutellaria barbatae, a chinese herb used for ovarian cancer, induces apoptosis of ovarian cancer cell lines. , 2003, Gynecologic oncology.

[27]  A. Riva,et al.  Silybin and its bioavailable phospholipid complex (IdB 1016) potentiate in vitro and in vivo the activity of cisplatin. , 2002, Life sciences.

[28]  A. Fattorossi,et al.  Antiproliferative effect of silybin on gynaecological malignancies: synergism with cisplatin and doxorubicin. , 1996, European journal of cancer.